Rolf Günther to steer Bicycle Therapeutics
This article was originally published in Scrip
Bicycle Therapeutics, the Cambridge, UK-based biotech firm that is developing a bicyclic peptide technology for the discovery of a new class of drug candidates with antibody-like selectivity and specificity but the potential for manufacturing at a similar cost to new chemical entities, has appointed Dr Rolf Günther as CEO. Previously, Dr Günther was CEO and COO of Affimed, where he will continue to serve as COO in a part-time role until August. Bicycle Therapeutics’ technology is based on discoveries made by its founders, Professor Christian Heinis and Sir Gregory Winter, at the MRC Laboratory of Molecular Biology in Cambridge.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.